Carprofen was pulled from the human market not because of a safety crisis, but because it was too expensive to manufacture. A 2025 review in Chemical Biology and Drug Design states plainly that carprofen’s use in humans was “discontinued shortly after its market launch due to costly raw materials, complex synthesis, and labor-intensive production processes,” making it uncompetitive against cheaper anti-inflammatory alternatives that were already widely available. The real story, though, has more layers than a simple business decision, and the drug’s afterlife in veterinary medicine adds a twist that surprises most people who hear about it for the first time.
What Carprofen Actually Was
Carprofen belongs to the propionic acid class of nonsteroidal anti-inflammatory drugs, the same chemical family as ibuprofen and naproxen. It was approved for human use in the 1980s, primarily for treating rheumatoid arthritis and osteoarthritis. A 1987 review described it as sitting in the middle of the NSAID potency range, roughly five times as potent as ibuprofen on a milligram-for-milligram basis and about one-quarter as potent as indomethacin.1PubMed. Carprofen: a new nonsteroidal antiinflammatory drug. Pharmacology, clinical efficacy and adverse effects It was dosed twice a day, which was considered a practical advantage at the time since some competing NSAIDs required three or four daily doses.
Clinical trials in rheumatoid arthritis patients showed a clear dose-response relationship. In a crossover study testing doses from 100 to 800 mg per day, the proportion of patients who responded climbed steadily with higher blood levels of the drug. About 69% of patients responded when drug concentrations were above a certain threshold, compared with only about 9% when concentrations were very low.2PubMed. Serum concentration and dose-response relationships for carprofen in rheumatoid arthritis So it worked, and for the patients it helped, it worked well enough to be a genuine treatment option.
The Commercial Problem That Ended Human Use
Carprofen’s synthesis was expensive and complicated. The raw materials cost more than those for competing NSAIDs, and the production process involved lengthy steps under strict conditions. A recent review characterized the situation bluntly: “Long synthesis steps, strict reaction conditions, and expensive raw materials were the reasons for carprofen’s withdrawal from human administration.”3PubMed Central. Synthesis Methods and Therapeutic Journey of Carprofen and Its Derivatives: A Review The NSAID market in the 1980s was crowded, with ibuprofen, naproxen, and indomethacin all well established, widely manufactured, and cheap. A drug that worked about as well as its competitors but cost more to produce simply could not survive commercially.
This is the part of the story most people find anticlimactic. When you hear “they stopped giving it to humans,” the assumption is that something went badly wrong: liver failure, cardiac events, a high-profile lawsuit. For carprofen, the manufacturer (Roche at the time) made a business calculation. The drug was not a blockbuster. It did not offer a dramatic safety or efficacy advantage over alternatives that were already generic or heading that way. It was not worth the ongoing investment in production.
Did Adverse Effects Play a Role?
This is where the picture gets muddier, because one source tells a slightly different story. A 2008 paper in the British Journal of Dermatology describes carprofen as having been “withdrawn due to adverse effects” before re-emerging for veterinary use in the 1990s.4PubMed. Occupational carprofen photoallergic contact dermatitis That framing is at odds with the more detailed 2025 review, which specifically attributes the withdrawal to commercial considerations and manufacturing costs. The truth likely sits somewhere in the overlap: adverse-effect reports probably contributed to the drug’s poor competitive position, even if they were not severe enough on their own to force a withdrawal.
Carprofen was an NSAID, and all NSAIDs carry gastrointestinal risks. But on that front, carprofen actually looked better than some alternatives. A study comparing carprofen and indomethacin in healthy volunteers found gastrointestinal injury in eight out of 20 indomethacin subjects and in none of the 20 carprofen subjects, suggesting less upper GI damage at comparable clinical doses.5PubMed. Effects of nonsteroidal, antiinflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers That was a meaningful advantage in a drug class where stomach damage was a constant clinical headache.
The adverse effects that did draw attention were less typical. Carprofen caused photosensitivity reactions in some people, meaning skin exposed to sunlight became inflamed after contact with the drug. This was documented most clearly in factory workers who handled carprofen during manufacturing. In one investigation, three out of eight workers with skin problems tested positive for photoallergic contact dermatitis to carprofen, and one of three healthy controls even developed an active photoallergy event after testing.4PubMed. Occupational carprofen photoallergic contact dermatitis These reactions were rare among patients taking the drug orally, but they were a liability, and they contributed to the sense that carprofen was more trouble than it was worth for a manufacturer already struggling with high production costs.
How Humans Process Carprofen Differently
One of the underappreciated details in carprofen’s history is how differently the drug behaves inside humans compared with other species. In humans, essentially the only significant way the body processes carprofen is by attaching a sugar molecule to it directly and excreting it. About 65 to 70% of an oral dose gets cleared through the urine this way, with most of the rest following the same route through bile.6PubMed. Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans In dogs and rats, by contrast, the body also oxidizes the drug into several different breakdown products before clearing them. Dogs in particular excrete about 70% of the drug through feces and only 8 to 15% through urine.
The human half-life ranged from roughly 13 to 26 hours across three subjects studied, while dogs showed a longer half-life of about 40 hours.6PubMed. Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans These metabolic differences matter because they influence how much of the drug accumulates, where it goes in the body, and what toxic byproducts it might produce. The simpler metabolic pathway in humans might seem like an advantage at first glance, since fewer breakdown products generally means fewer routes to toxicity. But the lack of alternative clearance pathways also means that if the primary route is overwhelmed or impaired, the drug has nowhere else to go.
The COX-2 Selectivity Irony
Here is the part of the story that researchers in the field find ironic. In the late 1990s, pharmaceutical companies spent billions developing a new generation of NSAIDs that selectively blocked the COX-2 enzyme rather than COX-1, the logic being that COX-2 drives inflammation while COX-1 protects the stomach lining. Drugs like celecoxib and rofecoxib (Vioxx) were launched with enormous fanfare. Meanwhile, carprofen had quietly been doing something similar all along.
Studies in canine cells showed that carprofen had the greatest selectivity for COX-2 of all the NSAIDs tested, with a potency for COX-2 more than 100-fold greater than for COX-1. The active form of the drug, the S enantiomer, was roughly 200-fold more potent against COX-2 than the R enantiomer.7PubMed. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs This selectivity profile is essentially what the later COX-2 inhibitors were designed to achieve, and it helps explain why carprofen caused less stomach damage than indomethacin in the human study mentioned earlier.
The selectivity picture is somewhat complicated by species and concentration effects. Work on bovine cells showed that S(+)-carprofen favored COX-2 inhibition, but the ratio of COX-1 to COX-2 blocking shifted at different drug concentrations. At low inhibition levels, the COX-2 preference was strong, but at higher levels of inhibition the advantage narrowed.8Research in Veterinary Science. Potency and selectivity of carprofen enantiomers for inhibition of bovine cyclooxygenase in whole blood assays Still, the general pattern held: carprofen was a COX-2-preferring drug before “COX-2 selective” was even a marketing concept. Had the timing been different, or the manufacturing costs lower, carprofen might have been repositioned as a first-generation COX-2 inhibitor rather than being dropped entirely.
The Stereo Chemistry Angle
Like ibuprofen and several other NSAIDs, carprofen exists as two mirror-image forms, known as enantiomers. The S(+) form does most of the anti-inflammatory work, while the R(−) form is much less active at the therapeutic target. The two forms also behave differently when binding to proteins in the blood, which matters because protein binding controls how much free drug is available to act on tissues. Research on how carprofen interacts with human serum albumin showed that the S(+) forms of carprofen and ibuprofen had the strongest interaction with each other when competing for binding sites, meaning that taking both drugs together could shift how much of each was active in the body.9Biochemical Pharmacology. Study of interaction of carprofen and its enantiomers with human serum albumin—II: Stereoselective site-to-site displacement of carprofen by ibuprofen
Drug companies in the 1990s and 2000s invested heavily in developing single-enantiomer versions of racemic drugs, since giving patients only the active mirror image can improve efficacy and reduce side effects. Carprofen was already off the human market by the time this approach became routine in the industry. In veterinary medicine, the racemic mixture (both forms together) continued to be used, and the drug’s COX-2 selectivity was attributed primarily to the S(+) enantiomer.
From Human Pharmacy to Veterinary Clinic
Carprofen’s second act began in the 1990s when Pfizer (later Zoetis) introduced it under the brand name Rimadyl for use in dogs. The economics that killed it in human medicine did not apply in the same way to veterinary use. The veterinary NSAID market was smaller, less crowded, and had fewer cheap generic competitors. Dogs with osteoarthritis, post-surgical pain, or chronic joint conditions needed effective anti-inflammatories, and carprofen’s COX-2 selectivity made it an attractive choice precisely because it spared the stomach lining more than older options.
The drug became one of the most widely prescribed veterinary pain medications in the world. But it was not without controversy in animals, either. Carprofen is commonly thought to carry a higher risk of liver toxicity in dogs than other veterinary NSAIDs, though a comparative study has never actually proven this. The veterinary labels for several other NSAIDs also list liver toxicity as a risk. What has been documented in more detail for carprofen is a pattern of idiosyncratic liver injury, where some dogs develop acute liver damage within about 14 to 30 days of starting the drug, with sharp increases in liver enzymes.10Veterinary Clinics of North America: Small Animal Practice. Idiosyncratic Drug Toxicity Affecting the Liver, Skin, and Bone Marrow in Dogs and Cats Isolated case reports have also described blood disorders during carprofen treatment, including low platelet counts and bone marrow damage, though these are very rare.
The term “idiosyncratic” is worth pausing on. It means these reactions are unpredictable. They do not follow a dose-response curve the way most drug side effects do. A dog getting a standard dose can develop severe liver injury while thousands of others on the same dose are fine. This unpredictability made carprofen a target for concern among some dog owners and veterinarians, but it is a feature of the entire NSAID class rather than a unique flaw of carprofen.
Carprofen and Cats
Cats present a separate and more cautious story. Felines metabolize many drugs more slowly than dogs, and carprofen is no exception. A pharmacokinetic study in cats found a long elimination half-life of about 20 hours, with significant individual variation.11PubMed. The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats A single intravenous dose did not produce visible gastrointestinal damage or significantly alter liver enzymes or blood counts in the study cats, which was reassuring. But the long half-life means the drug lingers, and repeated dosing raises the risk of accumulation.
Carprofen is sometimes used in cats as a single perioperative dose for pain management, but it is not widely licensed for repeated use in felines the way it is in dogs. Accidental overdose in cats can be serious. One published case report described a cat treated with intravenous lipid emulsion therapy after a carprofen overdose, supporting the idea that the drug’s fat-soluble nature allows it to be “mopped up” from the bloodstream using lipid infusions.12PubMed Central. Use of intravenous lipid therapy in a cat with carprofen overdose The cautious approach to cats reflects a broader principle in veterinary pharmacology: what is safe for dogs is not automatically safe for cats, especially when it comes to drugs that the liver must process.
What the NSAID Class Has Learned Since
Carprofen’s exit from human medicine happened before two seismic events reshaped the NSAID landscape. The first was the rise and fall of the COX-2 selective inhibitors. Rofecoxib (Vioxx), launched in 1999, was withdrawn in 2004 after evidence emerged of increased heart attack and stroke risk. That scandal raised questions about whether COX-2 selectivity, once seen as purely beneficial, might carry its own cardiovascular dangers. If carprofen had still been on the human market, its own COX-2 selectivity would have put it under the same scrutiny.
The second development was a deepening understanding of how all NSAIDs, not just specific outliers, can cause cellular damage through oxidative stress. Research has shown that carboxylic acid NSAIDs as a class can trigger the production of reactive oxygen species, damage DNA and cell membranes, and disrupt mitochondrial function. These effects tend to depend on dose and duration of use.13Taylor & Francis Online / Expert Opinion on Drug Metabolism & Toxicology. Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism None of this singles carprofen out specifically, but it underscores that every NSAID carries real risks that were less well understood in the 1980s.
Had carprofen been cheaper to make, it is plausible that it would still be prescribed to people today, sitting alongside ibuprofen and naproxen with its own set of warnings and precautions. Its GI safety profile was arguably better than some competitors, its COX-2 selectivity was ahead of its time, and its clinical efficacy was solid. The drug did not fail as medicine. It failed as a product. The distinction matters because it reveals how much the drugs that end up in your medicine cabinet are shaped by manufacturing economics, patent timing, and corporate strategy, not just by what works and what does not.
Carprofen’s Quiet Research Afterlife
Even off the human market, carprofen has not entirely left the research pipeline. Its chemical structure has served as a scaffold for developing new compounds with potentially improved properties. The 2025 review of carprofen’s synthesis methods focuses specifically on derivative compounds designed to overcome the manufacturing challenges that killed the original drug, exploring shorter synthesis routes and cheaper starting materials.3PubMed Central. Synthesis Methods and Therapeutic Journey of Carprofen and Its Derivatives: A Review Some of these derivatives are being explored for anti-cancer activity, anti-microbial effects, and other applications well beyond the original use as a simple pain reliever.
The idea of “drug repositioning,” where an existing compound finds new clinical uses in a different species or disease, is exactly what happened when carprofen moved from human rheumatology clinics to veterinary pain management. Whether any carprofen derivative circles back into human medicine remains to be seen, but the drug’s story is a useful reminder that a molecule withdrawn from one market is not necessarily a failed molecule. Sometimes the circumstances change, the economics shift, or the science catches up to what the compound was doing all along.